Cerity Partners LLC Raises Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Cerity Partners LLC lifted its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 151.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,878 shares of the biotechnology company's stock after buying an additional 30,637 shares during the period. Cerity Partners LLC's holdings in ADMA Biologics were worth $1,017,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Quest Partners LLC acquired a new position in ADMA Biologics during the 2nd quarter worth $29,000. Hollencrest Capital Management acquired a new stake in ADMA Biologics in the 3rd quarter valued at approximately $30,000. CWM LLC increased its position in ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company's stock worth $92,000 after buying an additional 4,367 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of ADMA Biologics in the second quarter worth $93,000. Finally, USA Financial Formulas boosted its holdings in ADMA Biologics by 8.6% in the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after purchasing an additional 539 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ADMA shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a "strong-buy" rating in a report on Friday, November 8th. Finally, HC Wainwright upped their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, November 8th.

Insider Activity at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the business's stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is owned by company insiders.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA traded down $0.63 on Thursday, hitting $19.32. The company had a trading volume of 2,127,493 shares, compared to its average volume of 3,614,928. The stock has a 50 day moving average price of $19.09 and a 200 day moving average price of $15.58. The stock has a market cap of $4.57 billion, a price-to-earnings ratio of 71.25 and a beta of 0.70. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same quarter last year, the business earned $0.01 earnings per share. Analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.